PEOPLE - Gish Biomedical (US) makes appointment:
This article was originally published in Clinica
Gish Biomedical, a US designer and manufacturer of disposable medical devices for surgical specialties such as cardiovascular surgery, orthopaedics and oncology, has appointed John Galuchie chairman. Mr Galuchie will also serve as interim CEO until a replacement is found for James Yarter, who has resigned for personal reasons.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.